The Turkish Journal of Pediatrics 2005 , Vol 47 , Num 1
Cardiac troponin I: is it a marker to detect cordiotoxicity in children treated with doxorubicin?
1Departments of Pediatric Oncology, Gülhane Military Academy and Faculty of Medicine, Ankara, Turkey
2Departments of Pediatric Oncology, Demetevler Oncology Hospital
3Departments of Pediatric Cardiology, Dr. Sami Ulus Children’s Hospital
4Düzen Medical Laboratory Group, Hacettepe University Faculty of Medicine, Ankara, Turkey
5Department of Pediatrics Cardiology Unit, Hacettepe University Faculty of Medicine, Ankara, Turkey
Köseoğlu V, Berberoğlu S, Karademir S, Kısmet E, Yurttutan N, Demirkaya E, Sungur M, Alehan D. Cardiac troponin I: is it a marker to detect cordiotoxicity in children treated with doxorubicin? Turk J Pediatr 2005; 47: 17-22.

Doxorubicin has been used in the the treatment of malignant tumors in children. Its use is limited by cardiotoxic effects beyond a cumulative dose of 450 mg/m2. To detect cardiotoxicity at an early stage and identify patients at risk for development of cardiotoxicity are matters of concern. Recently, cardiac troponin I (cTnI) has been reported to be useful for detecting minor myocardial damage. In the present study, we investigated whether cumulative doxorubicin-related myocardial cell damage can potentially increase cTnI levels above the expected values in 22 patients treated with cumulative doxorubicin doses of 120 to 450 mg/m2. Impaired cardiac functions were found in three patients by echocardiography, but serum CTnI levels were within the ranges expected in healthy individuals both in patients with cumulative doxorubicin doses .400 mg/m2 and in patients with disturbed cardiac functions. We found no relationship between serum cTnI, cumulative dose of doxorubicin, and echocardiographical findings. Keywords : cardiac troponin I, doxorubicin, cardiotoxicity

Copyright © 2016 turkishjournalpediatrics.org